Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Alpine Immune Sciences
Thumbnail
October 04, 2021

J&J breathes some more life into plamotamab and CD28

Two Xencor approaches with questions around them receive the backing of Johnson & Johnson.

Thumbnail
July 08, 2021

Why Glaxo should buy Biohaven

And four other potential targets that could make sense for the beleaguered group.

Article image
Vantage logo
July 01, 2021

Merck joins Alpine's CD28 efforts, but Regeneron leads

Article image
Vantage logo
June 09, 2021

Asco 2021 movers – PDS wins, but big pharma reigns

PDS and Spectrum rise, while Black Diamond, Alpine, Harpoon and Macrogenics disappoint, and others ride on big pharma’s coattails.

Article image
Vantage logo
June 04, 2021

Asco 2021 – Alpine hopes to banish the ghost of Tegenero

Article image
Vantage logo
May 21, 2021

Asco 2021 – Abstract lift drives first stock moves

A handful of small caps, including Sensei and PDS, jumped on Asco abstract data, with much more news to come.

Article image
Vantage logo
April 15, 2021

Glaxo follows Jounce with an Icos setback

Article image
Vantage logo
March 22, 2021

AACR 2021 preview – the early themes emerge

The most important of this year’s two virtual AACRs features immunotherapy combos, new Kras players and first clinical data for several assets.

Article image
Vantage logo
June 18, 2020

Alpine gets validation from Abbvie

Article image
Vantage logo
November 01, 2019

Upcoming events – key tests approach for Kadmon and Surface

Kadmon awaits key graft-versus-host disease data, and Surface Oncology's change of tack comes under the spotlight.

Article image
Vantage logo
November 21, 2018

Ash 2018 preview – blood cancers offer biotech a chance at redemption

The Ash meeting starts on December 1. Here are some haematological cancer presentations that investors will be focusing on, as biotech risks ending 2018 in poor shape.

  • Load More
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

February 17, 2023

PD(L)anner – February 2023

February 09, 2023

Biopharma and Medtech Review 2022

View more...

Editor's Picks

Vantage logo
March 13, 2023

Silicon Valley Bank: biopharma’s latest crisis

Vantage logo
March 13, 2023

Pfizer rescues biotech

Vantage logo
February 28, 2023

Why Pfizer (and others) will be interested in Seagen

Vantage logo
March 04, 2023

ACC 2023 – Esperion’s outcomes win looks lacklustre

Vantage logo
March 06, 2023

T-cell receptor behemoths consolidate? Not quite

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up